FDA Approves Nivolumab as Adjuvant Treatment for Melanoma
WEDNESDAY, Oct. 18, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved Opdivo (nivolumab) for the adjuvant treatment of completely resected stage IIB/C melanoma in patients ages 12 years and older.The approval was based on res…
Learn MorePositive Five-Year Outcomes Seen for Nivolumab in Resectable Lung Cancer
WEDNESDAY, Feb. 15, 2023 (HealthDay News) — For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant nivolumab is associated with positive five-year outcomes, according to a study published online Feb. 15 in Clinical Cancer Resear…
Learn More